<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">The introduction of new antiviral agents for clinical use has revolutionized the treatment of many viral infections caused by either DNA or RNA viruses (
 <xref rid="bib23" ref-type="bibr">De Clercq and Li, 2016</xref>; 
 <xref rid="bib25" ref-type="bibr">De Clercq, 2013a</xref>; 
 <xref rid="bib16" ref-type="bibr">Chaudhuri et al., 2018</xref>). Most of the approved drugs have been licensed for the treatment of infections caused by a single virus. However, some drugs with antiviral activity against several viruses have also been discovered, suggesting their universal mechanism of action. Such drugs belonging to the group of broad-spectrum antivirals are of particular interest since their pleiotropic effect may show activity against other viruses that have been undefined thus far (
 <xref rid="bib41" ref-type="bibr">Ianevski et al., 2018</xref>, 
 <xref rid="bib40" ref-type="bibr">2019</xref>). Recently, several approved antiviral and anticancer drugs from the nucleos(t)ide antimetabolite group have been reported to show newly discovered antiviral/antibacterial activities (
 <xref rid="bib45" ref-type="bibr">Jordheim et al., 2013</xref>; 
 <xref rid="bib99" ref-type="bibr">Thomson and Lamont, 2019</xref>).
</p>
